TOP TEN perturbations for NM_000229 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000229
Selected probe(set): 204428_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000229 (204428_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-3.8833256
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 9 (HBV) / normal liver tissue

Relative Expression (log2-ratio):-3.6061125
Number of Samples:10 / 10
Experimental HCC study 9 (HBV)
Liver tissue biopsy sample from patients with Hepatitis B infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 9 (alcohol; HCV) / normal liver tissue

Relative Expression (log2-ratio):-3.4082766
Number of Samples:4 / 10
Experimental HCC study 9 (alcohol; HCV)
Liver tissue biopsy sample from patients with alcohol abuse and Hepatitis C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HBV-related HCC study 1 / adjacent HBV-related liver tissue (CH)

Relative Expression (log2-ratio):-3.3276749
Number of Samples:5 / 4
Experimental HBV-related HCC study 1
Hepatitis B infection related human hepatocellular carcinoma sample.
Control adjacent HBV-related liver tissue (CH)
Histologically normal adjacent liver tissue of a patient with Hepatitis B infection related hepatocellular carcinoma. Patient with chronic hepatitis.

HCC study 18 (very advanced) / normal liver tissue

Relative Expression (log2-ratio):-3.207159
Number of Samples:3 / 10
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control normal liver tissue
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.

HCC study 9 (alcohol) / normal liver tissue

Relative Expression (log2-ratio):-2.8498974
Number of Samples:24 / 10
Experimental HCC study 9 (alcohol)
Liver tissue biopsy sample from patients with alcohol abuse related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 3 (area A) / HCC study 3 (area D)

Relative Expression (log2-ratio):-2.7547922
Number of Samples:13 / 19
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area D)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken in an area 2-3 cm away from the tumor (area D). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 9 (HCV) / normal liver tissue

Relative Expression (log2-ratio):-2.7468157
Number of Samples:9 / 10
Experimental HCC study 9 (HCV)
Liver tissue biopsy sample from patients with Hepatitis C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 3 (area A) / HCC study 3 (area C)

Relative Expression (log2-ratio):-2.7463322
Number of Samples:13 / 24
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area C)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 18 (very advanced) / hepatitis C study 10

Relative Expression (log2-ratio):-2.7070704
Number of Samples:3 / 13
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control hepatitis C study 10
Cirrhotic tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Ten out of 13 samples were obtained from patients with hepatocellular carcinoma. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.